Skip to main content
SpringerLink
Log in

Effects of Inhaled Corticosteroids on Mortality and Hospitalisation in Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients

Appraising the Evidence

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are common conditions that have substantial effects on daily functioning and medical resource utilisation. In elderly populations, the use of inhaled corticosteroids (ICS) as a mainstay of treatment in asthma has long been accepted whereas the appropriateness and extent of use of ICS in COPD is not as clear. This paper reviews data associated with ICS treatment in the elderly, specifically characteristics of ICS users, rates of adherence, hospitalisation and mortality associated with ICS treatment.

Studies examining the use of ICS in asthma and COPD have generally found that ICS may be underused compared with guideline recommendations or that there are substantial differences between patients who receive ICS and those who do not. Among elderly asthma or COPD patients who receive ICS, there are lower rates of hospitalisation among those who adhere to their treatment plan. Among elderly patients with asthma, the combination of ICS plus long-acting β-adrenoceptor agonists has been shown to be superior in terms of mortality and hospitalisation compared with either treatment alone. There may be an interaction effect between oral corticosteroids and ICS among elderly COPD patients, although important differences may be present in the clinical characteristics of patients who receive one versus both forms of corticosteroids. A dose-response relationship between ICS and both all-cause and pulmonary-specific mortality has been shown among older COPD patients.

Several existing studies are subject to selection bias, as they have identified patients who survived for a specified period, for example, long enough to have received a specified number of prescriptions for ICS. This bias must be further explored. Future research should also clearly delineate asthma and COPD populations in order to identify different benefits from ICS. The use of a claims database that also includes clinical metrics would be useful to identify additional possible outcomes of ICS use. Further, symptom diaries or other patient-reported outcomes, such as health-related quality of life and health status, should be included in studies of ICS among the elderly to identify other benefits that should be considered in treatment selection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2(1): 67–74

    Article  PubMed  CAS  Google Scholar 

  2. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003 May; 123(5): 1684–92

    Article  PubMed  CAS  Google Scholar 

  3. Morbidity and mortality: 2004 chart book on cardiovascular, lung, and blood diseases [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. [Accessed 2004 Dec 13]

  4. World Health Organization. Bronchial asthma: the scale of the problem. Fact sheet No. 206, 2000 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs206/en/ [Accessed 2005 Aug 3]

  5. National Heart, Lung, and Blood Institute. Global Initiative for Asthma: global strategy for asthma management and prevention. NIH publication number 02-3659: updated 2002. Bethesda (MD): National Institutes of Health, 2002

    Google Scholar 

  6. Rich A. Corticosteroids and chronic obstructive pulmonary disease in the nursing home. J Am Med Dir Assoc 2004 Jan–Feb; 5(1): 31–37

    Article  PubMed  Google Scholar 

  7. Pauwels RA, Barnes PJ. Pro-con debates on controversial clinical issues: inhaled corticosteroids are beneficial in COPD. Paper presented at Annual Meeting of the American Thoracic Society; 2002 May 20; Alatana (GA)

  8. Balkrishnan R, Christensen DB. Inhaled corticosteroid nonadherence and immediate avoidable medical events in older adults with chronic pulmonary ailments. J Asthma 2000 Sep; 37(6): 511–7

    Article  PubMed  CAS  Google Scholar 

  9. Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clin Ther 2000 Apr; 22(4): 452–69

    Article  PubMed  CAS  Google Scholar 

  10. Blais L, Bourbeau J, Sheehy O, et al. Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment. Can Respir J 2004 Jan–Feb; 11(1): 27–32

    PubMed  Google Scholar 

  11. Bourbeau J, Ernst P, Cockcoft D, et al. Inhaled corticosteroids and hospitalisation due to exacerbation of COPD. Eur Respir J 2003 Aug; 22(2): 286–9

    Article  PubMed  CAS  Google Scholar 

  12. Diette GB, Krishnan JA, Dominici F, et al. Asthma in older patients: factors associated with hospitalization. Arch Intern Med 2002 May 27; 162(10): 1123–32

    Article  PubMed  Google Scholar 

  13. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003 Dec 15; 168(12): 1488–94

    Article  PubMed  Google Scholar 

  14. Jackevicius C, Joyce DP, Kesten S, et al. Prehospitalization inhaled corticosteroid use in patients with COPD or asthma. Chest 1997 Feb; 111(2): 296–302

    Article  PubMed  CAS  Google Scholar 

  15. Schols AM, Wesseling G, Kester AD, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001 Mar; 17(3): 337–42

    Article  PubMed  CAS  Google Scholar 

  16. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003 Feb; 21(2): 260–6

    Article  PubMed  CAS  Google Scholar 

  17. Sin DD, Tu JV. Underuse of inhaled steroid therapy in elderly patients with asthma. Chest 2001 Mar; 119(3): 720–5

    Article  PubMed  CAS  Google Scholar 

  18. Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001 Mar; 17(3): 380–5

    Article  PubMed  CAS  Google Scholar 

  19. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002 Oct; 20(4): 819–25

    Article  PubMed  CAS  Google Scholar 

  20. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003 Jul 1; 168(1): 49–53

    Article  PubMed  Google Scholar 

  21. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004 Mar; 23(3): 391–5

    Article  PubMed  CAS  Google Scholar 

  22. Schmier JK, Leidy NK. The complexity of treatment adherence in adults with asthma: challenges and opportunities. J Asthma 1998; 35(6): 455–72

    Article  PubMed  CAS  Google Scholar 

  23. Murray MD, Morrow DG, Weiner M, et al. A conceptual framework to study medication adherence in older adults. Am J Geriatr Pharmacother 2004 Mar; 2(1): 36–43

    Article  PubMed  Google Scholar 

  24. van Walraven C, Davis D, Forster AJ, et al. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 2004 Jul; 57(7): 672–82

    Article  PubMed  Google Scholar 

  25. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004 Oct 1; 170(7): 760–5

    Article  PubMed  Google Scholar 

  26. Donohue JF, Kalberg C, Emmett A, et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004; 3(3): 173–81

    Article  PubMed  CAS  Google Scholar 

  27. Dal Negro RW, Pomari C, Tognella S, et al. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003; 16(4): 241–6

    Article  Google Scholar 

  28. Spencer S, Calverley PM, Sherwood Burge P, et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 Jan; 163(1): 122–8

    PubMed  CAS  Google Scholar 

  29. Halpern MT, Higashi MK, Bakst A, et al. The economic impact of acute exacerbations of chronic bronchitis (AECB) in the US and Canada: a literature review. J Manag Care Pharm 2003; 9(4): 353–9

    PubMed  Google Scholar 

  30. Leidy NK, Rennard SI, Schmier JK, et al. The breathlessness, cough, and sputum scale (BCSS): the development of empirically-based guidelines for interpretation. Chest 2003; 124(6): 2182–91

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No funding was received for the preparation of this manuscript and the authors are not currently receiving any funding directly related to the contents of the manuscript.

The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Exponent Inc., 1800 Diagonal Road, Suite 300, Alexandria, Virginia, 22314, USA

    Jordana K. Schmier,  Michael T. Halpern & Mechelle L. Jones

Authors
  1. Jordana K. Schmier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael T. Halpern
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mechelle L. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael T. Halpern.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmier, J.K., Halpern, M.T. & Jones, M.L. Effects of Inhaled Corticosteroids on Mortality and Hospitalisation in Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients. Drugs Aging 22, 717–729 (2005). https://doi.org/10.2165/00002512-200522090-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200522090-00001

Keywords

Search

Navigation